Wednesday, 11th November Clinical Oncology Society of Australia Annual Scientific Meeting 2020

• Introduction to implementation science & oncology  - Bogda Koczwara
• Considering a Dynamic, Evolutionary Approach to Implementation Science: Assumptions, Implications and Future Directions - David A Chambers
• The Science of Implementing Health Information Technology Requires the Art of Requisite Imagination     - Hardeep Singh
• Translating ideas into action: Lessons from the COSA Tele-Trial project  - Sabe Sabesan

10:15 AM Panel Discussion

• Sustaining paclitaxel administration in the era of ranitidine shortages - Marissa Ryan
• Biosimilars- Sustaining the cost of biologics. A snapshot at a metropolitan hospital. - Christine Carrington
• Fixed dosing of immunotherapy - profit ahead of sustainability?  - Jim Siderov
• Avoiding a Total Eclipse of the Heart: Sustaining Cardiac Function During Cancer Therapy  - Michael Powell
• Home chemotherapy - Sustaining care for patients  - Gail Rowan

• Mental Health and co-design in working with Aboriginal communities  - Maree Toombs
• Supporting patients with pancreatic cancer and their carers: Lessons from a nurse-led telephone counselling pilot - Vanessa L Beesley
• The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients - Bettina Meiser
• Of course you smoke! Responding to the stigmatised patient population: lung cancer survivorship and potential areas for implementation  - Nicole Rankin

12:05 PM Panel Discussion 

• Current practice for population-based mammography  - Partha Basu
• A Radiologic perspective of cost, time and doesages accrued in the course of cancer treatment  - Sonja Gustafson
• Financial and emotional burden of repeated scans – the patient perspective - Gail McDonald
• Difficulties accessing scans in regional areas; survivorship/follow-up guidelines for sharing scans to avoid doubling up  - Neil Wylie

12:05PM Panel Discussion

• Advanced cancer patient preferences for receiving molecular profiling results - Megan Best
• Respiratory physiotherapy is safe in the management of patients post airway stent insertion. - Laura Daly
• CHK1 inhibitor + subclinical dose of hydroxyurea selectively kills melanomas and enhances immune responses in the tumour micro-environment that synergise with immune checkpoint inhibitors in vivo.  - Brian Gabrielli

12:51 PM Discussion 

• Saving the heart with radiation therapy for breast cancer - Tamara J Barry
• The Value of including CardioOncology review for Patients undergoing Thoracic Irradiation - Daniel A Cehic
• Impact of Allogeneic Stem Cell Transplant on the cardiovascular health of haematological cancer patients - Hayley T Dillon

12:51 PM Discussion

• The impact of personal melanoma genomic risk information on skin cancer prevention behaviours and psychosocial outcomes - a randomised controlled trial - Anne E Cust
• Identifying patterns of comorbidities with cancers of the colon and rectum, as related to age at diagnosis - Kazzem Gheybi
• What cancer survivors die of. A population-based Australian study of late mortality after cancer. - Bogda Koczwara

12:51 PM Discussion

Implementation science is at the core of the Cancer Alliance Queensland safety and quality program. Through a variety of mechanisms; data analysis, customised hospital reporting, dashboards, clinical review and feed back to clinical teams Cancer Alliance Queensland promotes the systematic uptake of key findings into routine practice.  

We take a deep dive into the Queensland Oncology Repository (a data lake) to uncover extensive data resources and insights of practical value to cancer care services, highlighting where the health system is performing well and identifying areas for improvement.

The plenary will comprise 4 oral papers based on population data from the Queensland Oncology Repository which describe the multisided QOOL platform or ‘air bnb’ of cancer data, novel approaches using natural language processing to determine cancer stage and recurrence, assessment of guideline concordant care in the colorectal cancer population and insights into management of adolescent and young adult cancer across Queensland.

The presentations will showcase the commitment of clinicians to creating a “learning cancer care system” which through systematic continuous quality monitoring, data analytics and application of such data informs overall strategies and targeted improvement efforts. The “learning cancer care system” inspires reflection and self-examination of performance in the local setting.  This is an essential tool which aids cancer clinicians in evaluating the delivery of cancer services in Queensland.

The papers will be followed by a panel discussion to explore the following key issues. How do we address implementation gaps across services? Where is a renewed effort needed to improve services? What is acceptable variation in cancer management?

1:30 PM Jeremy Long - Introduction

1:35 PM Shoni Philpot
Transforming digital data into cancer care practice: implementation science in action

1:45 PM Danica Cossio
Natural language processing; a novel approach to determine stage and recurrence for 5 cancer populations

1:55 PM Rick Walker
Utilising big data to inform the management of AYA cancer in Queensland

2:05 PM Euan Walpole
Performing well & room for improvement; spotlight on CRC guideline concordant care

2:15 PM Panel Discussion 

• Transforming digital data into cancer care practice: implementation science in action  - Shoni Philpot, Danica Cossio, Euan Walpole and Rick Walker

• Melanoma Recurrence Patterns and Management after Adjuvant Targeted Therapy: A Multicentre Analysis - Prachi Bhave
• The International Lung Screening Trial: opportunistic screening for osteoporosis using low-dose chest CT; baseline findings - Nikita Botadra
• Osimertinib as adjuvant therapy in patients with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumour resection: ADAURA - Thomas John
• Outcomes in rare cancer patients who underwent comprehensive genomic sequencing in the NOMINATOR study. - Damien Kee
• Real-world uptake of bone modifying agents in advanced breast cancer with bone metastases – prospective data from a multi-site Australian registry. - Vanessa Wong

3:30 PM Discussion

• 10 years of medical fertility preservation at a tertiary centre in Australia (2009-2019): What have we learnt to inform future program provision? - Violet Kieu
• Developing clinical indicators for Oncology: the inaugural indicator set for The Australian Council on Healthcare Standards (ACHS) - Eva Segelov
• Assessing the effect of immunotherapy-induced thyroid dysfunction on the prognosis of oncology patients: A Systematic Review and Meta-Analysis - Sam Tafari
• COVID-19 Recovery: Implications for cancer care - Vivienne Milch

3:20 PM Discussion

• Does an educational intervention increase radiation therapists’ confidence and knowledge in administering an electronic patient symptom and distress screening tool? - Belinda Arnold
• Clinician perspectives of distributed health literacy in adolescents and young adults with cancer and their families - Danielle Gessler
• Clinical strategies to building health literacy in adolescents and young adults with cancer and their families - Danielle Gessler
• Pilot study of an online training intervention to increase genetic literacy and communication skills in oncology healthcare professionals discussing genetic testing with breast and  ovarian cancer patients    - Bettina Meiser
• Cancer and COVID-19: delivering strategic health communication during a pandemic - Carolyn Der Vartanian

3:30 PM Discussion

• Where are we at in the implementation science of patient reported outcome measures (PROMs)?  - Afaf Girgis
• Implementations of PROMS: Achieving system efficiencies - Bena Brown
• Feasibility of a statewide approach to the implementation of PROMS in routine cancer care - Penelope M Webb
• Setting an exemplar for system connectivity for PREMS - Leanne Stone

5:20 PM Panel Discussion

• Mainstreaming Genetic Testing - Camron Ebzery
• Breast Cancer Polygenic Risk Scores: A Review of Clinical Utility and the Ethical, Legal and Social Implications of an Emerging Field - Tatiane Yanes
• Using implementation science to improve Lynch syndrome genetic referral practices among colorectal cancer patients  - April Morrow
• Upskilling Non-genetics Physicians to offer Genetic Testing for Melanoma - Aideen McInerney-Leo

• Developing and implementing a comprehensive consumer engagement framework  - Sophy Athan
• Problems and pitfalls in consumer partnership  - David Clune
• Partnering for person-centred services  - Catherine Devereux
• Consumers as Partners in Bedside Professional Development Education for Nurses  - Monique Richter

5:20 PM Panel Discussion

Time: 6:00pm - 7:00pm AEDT

Description: Real-world evidence (RWE) leveraging observational registries and claims databases has been commonplace for several years and is a concept that has been long-present in healthcare industry. This session will cover the evolving role of RWE in Australia.

Chair: 
Prof John Zalcberg, Head of Cancer Research and NHMRC (MRFF) Practitioner Fellow within the School of Public Health and Preventive Medicine at Monash University and Tony Charlton Chair of Oncology at Alfred Health
Prof Andrew Wilson, Chair of the PBAC
Amanda Ruth, Head of Policy and Public Affairs at Rare Cancers Australia
Simone Leyden, Co-Founder and CEO at NeuroEndocrine Cancer Australia
Michael Coory, Medical Officer, Technology Assessment and Access Division, Department of Health
Dr Margaret Wilson, Dr Sarah Golding, Senior Medical Officer, TGA

Speakers: 
Prof Andrew Wilson
Amanda Ruth
Prof John Zalcberg

This symposium is available for virtual attendees. Please register using the button below.

This evening symposium is sponsored by Medicines Australia

Time: 7:00pm - 8:30pm
Date: 11 November 2020

Learning Objectives

The emergence of subsidized immuno-oncology (IO) therapy for the treatment of melanoma in the advanced and adjuvant setting has transformed the way that patients are treated and managed.
During this symposium, our Chair and Speakers will help you understand the latest evidence for KEYTRUDA® (pembrolizumab) and discuss best practice treatment and management considerations for your melanoma patients in both the adjuvant and advanced settings.

By the end of the meeting, you’ll gain:

• Understanding of the evidence behind KEYTRUDA® in adjuvant & advanced Melanoma
• Understanding of difference in treatment and management considerations of adjuvant & advanced Melanoma
• Practical tips in the implementation of KEYTRUDA® in clinical practice of adjuvant & advanced Melanoma

Chair: A/Prof Victoria Atkinson, Medical Oncologist, Princess Alexandra Hospital

Speakers: 

A/Prof. Melissa Eastgate, Deputy Director of Medical Oncology, Royal Brisbane and Women’s Hospital

Rebecca Johnson, Clinical Nurse Consultant, Melanoma Institute Australia

This evening symposium is sponsored by MSD Australia

• Locally advanced oesophageal cancer: a descriptive analysis to review outcomes of perioperative ECF chemotherapy vs neoadjuvant CROSS regime chemoradiotherapy at an Australian Regional Centre - Bridget Josephs
• Idronoxil combined with cisplatin rescues refractory immune responses in nasopharyngeal carcinoma - Ngar Woon Kam
• Colorectal cancer survivorship: A systematic review and thematic synthesis of qualitative research - Chloe Y. S. Lim
• MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer - Neil Portman
• Therapeutic inhibition vs. intestinal deletion of CYP24A1 and its effects on chemotherapy-induced gastrointestinal mucositis - Cyan L Sylvester
• Hospitalisations in phase I solid tumour clinical trial patients: incidence, pattern and clinical outcomes – our experience at a Western Australian dedicated phase I clinical trial unit.  - Mihitha Ariyapperuma
• Drug repurposing for cancer treatment – an examination of drug development trials, regulation and financing. - Anneke C Blackburn
• Abemaciclib combined with endocrine therapy for the adjuvant treatment of high-risk early breast cancer. - Frances Boyle
• The utility of surveillance CT scans in a cohort of survivors of colorectal cancer - Jorja Braden
• Characteristics and outcomes of patients with advanced thoracic malignancies admitted to the intensive care unit of a tertiary hospital in Sydney - Lauren Brown
• The effects of a family-centered psychosocial-based nutrition intervention in patients with advanced cancer: the PiCNIC2 pilot randomised controlled trial - Teresa Brown
• Ability of Radiation Therapists to accurately detect mask anxiety in people with head and neck cancer - Melissa Burns
• BRAF/MEK Inhibitors for BRAF V600E-mutant cancers in non-approved setting - Sabeeh-ur-Rehman Butt
• Systemic treatment with a RET inhibitor (LOXO-292) in a patient with metastatic colorectal cancer with RET fusion (NCOA4-RET). - Sabeeh-ur-Rehman SB Butt
• Combination Netupitant and Palonosetron for the prevention of delayed nausea and vomiting in patients undergoing conditioning with Melphalan-containing regimens for Autologous Stem Cell Transplantation                 - Nadia Chee
• Can the H-index score predict treatment failure for Oropharyngeal Squamous Cell Carcinoma - Sanith Cheriyan
• Pilot clinical and pharmacokinetic study of a water soluble nanoparticle cannabis-based medicine in advanced cancer with intractable pain. - Stephen Clarke
• Exploration of current dietetic practices for patients with gynaecological cancers undergoing radiotherapy in Australia: a cross sectional survey - Emilie Croisier
• Metabolic Tumour Volume (MTV) on 18-Fluorodeoxyglucose Positron Emission Tomography (FDGPET) as a prognostic marker of survival in patients with Metastatic Neuroendocrine Neoplasms (mNENs) receiving ¹⁷⁷Lutetium-DOTA-octreotate (Lutate). - Madhawa De Silva
• First-line liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: results from a phase 1/2 study - Andrew Dean
• Changes in body composition and sarcopenia status with four weeks of HIIT in breast and prostate and colorectal cancer survivors   - Morgan J Farley
• Trends in adverse events over the treatment course in patients on chemotherapy for recurrent platinum-sensitive ovarian cancer.  - Katherine E Francis
• Do Histopathological features of Breast Cancer in Australian Indigenous Women explain the survival disparity? A two decade long study in the Northern Territory - Sophia Frentzas
• Results of crossover phase 2 component of randomised placebo-controlled trial evaluating oral THC/CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting (CINV) - Antony Mersiades
• Long-term Haematologic Toxicity of ¹⁷⁷Lu-PRRT CAPTEM Chemotherapy of GEPNET - Piyush Grover
• Systematic review and meta-analysis of treatment related toxicities from second-generation androgen receptor inhibitors in advanced prostate cancer - Sana Haider
• Melanoma Margin Trial (MelMarT-II): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma. - Junya Eguchi
• Phase 3 LEAP-006 Safety Run-In (Part 1): 1L Pembrolizumab + Chemotherapy With Lenvatinib for Metastatic NSCLC - Baerin Houghton
• Retrospective study on Pneumocystis jirovecii Pneumonia (PJP) prophylaxis in advanced cancer patients requiring immunosuppression from immune-related adverse events - Saw Htut
• Investigating disparities in pancreatic cancer care: outcomes in patients of limited English proficiency - Alexander Kilner
• The role of Telehealth for cancer patients in Australia - Lyn Ley Lam
• The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: an open-label, randomized phase 2 study - Elgene Lim
• Optimal upfront treatment in surgically resectable pancreatic cancer: A higher volume centre retrospective analysis - Sarah Maloney
• Health-Related Quality of Life (HRQoL) at final analysis of the SPARTAN study of Apalutamide (APA) vs Placebo (PBO) in patients (pts) with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) receiving Androgen Deprivation Therapy (ADT) - Siobhan Ng
• Immunotherapy in elderly cancer patients - utility of a Comprehensive Geriatric Assessment (CGA) - Phuong Phan
• Patterns of care and outcomes of elderly patients with resected stage III colorectal cancer in Australia - Oliver Piercey
• Systemic therapy at end of life in patients with solid organ malignancy  - Omali Pitiyarachchi
• Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) - Timothy Price
• Comparison of body composition methodology in patients with head and neck cancer: bioelectrical impedance analysis vs computed tomography analysis - Teresa Brown
• Ribociclib tolerability and toxicity: a retrospective study at two tertiary centres - Brenton Seidl
• Is adjuvant pelvic radiation therapy after local excision or polypectomy for T1 and T2 rectal cancer an appropriate treatment approach? - Carmen Swanton
• Metastatic Breast Cancer Profile in MRCCC Siloam Cancer Hospital Jakarta - Jeffry Tenggara
• Real-world treatment patterns and survival outcomes for small cell lung cancer (SCLC): experience from the Sunshine Coast hospital and health service (SCHHS). - Cassie Turner
• Qualitative exploration of intention to change behaviour in patients undertaking genome sequencing - Sabina Vatter
• Deriving stage at diagnosis from multiple clinical and population-based sources: Non-small cell lung cancer in Queensland - Morgan Windsor
• Single centre retrospective study of outcomes in patients with metastatic melanoma who progress on 1^st line immunotherapy. - Zane Yang
• Age of uncertainty: the management of older patients diagnosed with colorectal cancer - Chen Yong
• Real-world tolerance and outcomes to oxaliplatin-based adjuvant chemotherapy for stage III colon cancer - does dose intensity matter? - Robert Yoon
• Phase 2 trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): results by independent imaging review and subgroup analyses - Chung-Han Lee
• Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC) - Vicky Makker
• Fiducial-based image-guided radiotherapy for upper gastrointestinal tumours: interim results on the success of liquid fiducials inserted through standard gastroscopy injection technique - Leonardo Zorron Cheng Tao Pu
• Cardiovascular health is impaired in men with prostate cancer prior to treatment - Ashley Bigaran
• Real World Outcomes in Elderly Patients with HER2 Positive Advanced Breast Cancer - Nicole Evans
• Case report of Abatacept use in Immune checkpoint induced steroid-refractory myocarditis - Vinod Kalapurackal Mathai
• Interventions to manage cardiovascular disease risk in cancer patients and survivors: an umbrella review - Emma Kemp
• Presentation, clinical course and management strategies for immune-related cardiac toxicities - Niamh O'Neill
• Nivolumab-induced myocarditis and myasthenia gravis crisis - Alborz AS Shahsavand
• Real-life incidences of intracardiac metastases in neuroendocrine neoplasms - Laura Tam
• Building distributed health literacy in adolescents and young adults with cancer through network-focused nursing  - Danielle Gessler
• Evaluating the effectiveness of the YMCA Cancer Survivors Program - Eliza Keating
• The iSCREEN study. Every patient. Every need. Developing and evaluating a web-based portal to screen for patient reported outcomes in cancer. A study protocol. - Reegan Knowles
• Designing a prostate cancer specialist nurse service to meet the needs of patients: A mixed methods approach - Natasha Roberts
• Why do we use intrathecal methotrexate in DLBCL? Co-creation of an updated guideline for our health service - Lachlan Roth
• Should we text patients COVID-19 data? - Ilana J Solo
• Building capacity from within - upskilling healthcare professionals to lead an evidence-based implementation approach - April Morrow
• Adaptation and evaluation of a smoking cessation clinical pathway implemented within cancer services - Alison L Young
• Retrospective analysis of chemotherapy-induced febrile neutropenia; Local experience towards risk-based management - Arwa Abdelmogod
• Clinical audit of chest drain complications in medical oncology patients - Stephanie Bailey and Romy Ehrlich
• A feasibility study measuring the ability to use the American Society of Clinical Oncology Quality Oncology Practice Initiative - Jo Ann Chow
• Frequency of Checkpoint Inhibitor Induced Immune Related Adverse Events requiring hospitalisation in routine clinical practice - Ashley Tan
• Outcomes of Patients with Metastatic Cancer Following Unplanned Medical Admission to Intensive Care Units (ICU). - Timothy D Clay
• Improving Febrile Neutropenia Management via Audit of Clinical Care - Timothy D Clay
• Developing standards of quality survivorship care – an online modified reactive Delphi study - Karolina Lisy
• Testing times: How ensure quality and safety in DIY diagnosis? - Tarishi Desai
• A systematic review of multidisciplinary colorectal cancer quality indicators - Candice Donnelly
• Pilot of a statewide patient reported outcomes survey for chemotherapy - Spiridoula Galetakis
• The role of a Geriatric Oncology service in building resilience during the COVID-19 pandemic - Harry Gasper
• Caregiver burden and experience of an Australian geriatric oncology population during COVID-19 pandemic - Harry Gasper
• Pilot evaluation of a ward liaison nurse for improved oncology care in a regional centre - Chloe L Georgiou
• The effect of the COVID-19 pandemic on patient recruitment to the Australasian Leukaemia and Lymphoma Group's clinical trial portfolio.  - Tracey Gerber
• Measuring quality changes during COVID-19 to cancer multi-disciplinary meetings in Victoria by survey - Anna Hedigan
• Thirty-day mortality for checkpoint inhibitors in metastatic cancer: A retrospective audit of medical oncology patients at Fiona Stanley Hospital - Samantha Hodges
• Evaluation of a pharmacist-led oral-anti-cancer clinic using a novel method at an Australian quaternary hospital - Johnathan Soggee
• Assessing and improving timeliness of radiation delivery in regional radiotherapy centres - Nooshin Dr Jahromi
• Piloting an online professional development program for junior oncology doctors personalised using EMR Data - Anna Janssen
• Could your workflow be costing you reimbursement? A re-audit post-intervention of missed dispensing for ten high cost parenteral cancer medicines. - Jacqueline A Leggett
• Patterns of oxycodone controlled-release use in older people with cancer following public subsidy of oxycodone/naloxone formulations: An Australian population‐based study - Melanie Lovell
• Treatment outcomes in an institutional cohort of female patients with anal SCC undergoing definitive chemoradiation - Caroline Lum
• Patient & clinician feedback of the Telehealth-Video consultations during COVID 19 Pandemic- challenges and opportunities. - Bipin Manezhi
• Who you gunna call? GP cancer referral hotline - Cheryl Martin
• Recruitment, outcomes and toxicity trends in phase I oncology trials: six-year experience in a large institution - Siddharth Menon
• Clinical outcomes in patients with locally advanced head and neck cancer (LA HNSCC) receiving Cisplatin versus non-Cisplatin chemotherapy - Siddharth Menon
• The cost of free drugs: The operational workload involved in the management of Medicine Access Programs - Hala Musa
• Outcomes of using cancer immunotherapy in elderly patients with lung cancer in an Australian tertiary metropolitan hospital - Elias Salagaras
• Understanding the Role of Specialist Follow-up in Early Breast Cancer, A Retrospective Review. - Zhen Rong Siow
• “We’re saving your life here. Why would you worry about a few hundred dollars here and there?” Findings from focus group discussions about the costs of cancer - Danielle Spence
• Quality of mHealth interventions in cancer survivors - Timothy Tune
• Improving the systematic management and delivery of oral cancer systemic therapies (OST) at a rural outreach cancer clinic: A quality improvement project from Gympie day oncology unit. - Arabella Widders
• Evaluation of a  virtual meeting platform for statewide oncology education during the COVID-19 pandemic - Vladimir Andelkovic
• What impact does participation in an intensive three-day communication skills retreat have for participants? Findings from qualitative interviews. - Ellen Webber
• Posterior Reversible Encephalopathy Syndrome (PRES) secondary to Pembrolizumab  - Karan Gupta
• Cancer prone behavior pattern and their interaction with smoking - Aleksandra Kizior
• Barriers to participation in breast and cervical cancer screening (Analysis of international research) - Aleksandra Kizior
• Investigating symptoms of lung cancer: a guide for all health professionals - Vivienne Chipman
• Impact of the COVID- 19 pandemic on current Medical Oncology trainees in Victoria - Rachel Raju
• Evaluation of Counterpart Navigator information app for women with breast or a gynaecological cancer - Linda Rehill
• Patient concerns and nocebo effect when pharmacy educated prior to switching from originator to biosimilar - Marissa Ryan
• The Oncology Journal Club Podcast ‐ an innovative format delivering oncology education - Eva Segelov
• Docetaxel Induced Necrotizing Fasciitis: A rare complication of chemotherapy - Ricci Steven
• Malignant mesothelioma in Australia: an update from the Australian Mesothelioma Registry (AMR) - Tim Driscoll
• Associations of cancer-related cognitive impairment with work and occupational functioning when controlling for distress and fatigue - Heather J Green
• Patterns of care for patients with non-neutropenic fevers during cytotoxic chemotherapy at a Regional University Hospital - Tivya Kulasegaran
• Cancer care in the time of COVID-19: A conceptual framework - Rhona Wang
• Quality of life and survival after pancreatic resection– A cross-sectional study - Clare Toms
• Modelling the health outcomes of immuno‐oncology therapies in cancer care in Australia – Reimbursement scenario analysis - Elias Toomeh
• Defining the future of paediatric fertility care – the establishment of The Australian and New Zealand Paediatric Oncofertility Coalition - Catherine Allingham
• Development of evidence-based clinical pathways for symptom management in patients with upper gastrointestinal cancer: A multidisciplinary approach - Lisa Brady
• Implementation of Structured Interdisciplinary Bedside Rounds in Cancer Care: Evaluation from an Allied Health perspective - Teresa Brown
• A Shift Towards Virtual Multidisciplinary Tumour Board Meeting During COVID 19 Pandemic – A South Australian Survey - Mei Mei Chan
• Regional and remote cancer patients’ experiences of healthcare services - Fiona Crawford-Williams
• Enhanced-recovery after surgery and early oral feeding for head and neck surgery cancer patients. - Sarah Day
• Barriers to Home Bowel Cancer Screening - Belinda C Goodwin
• Patient and carer experience of nutrition care throughout and beyond treatment for head and neck cancer:  a qualitative longitudinal study  - Joanne Hiatt
• Retrospective study on Hepatitis B screening and risk of HBV Reactivation in Immune Checkpoint Inhibitor Therapy for advanced cancer patients - Saw Htut
• Attitudes towards data sharing and secondary analysis in cancer; preliminary results of a healthcare consumer questionnaire - Elizabeth Hutchings
• Attitudes towards data sharing and secondary analysis in cancer; preliminary results of a questionnaire in researchers and/or healthcare professionals - Elizabeth Hutchings
• Cancer survivors’ needs, preferences, and experiences accessing dietary information post-treatment: A scoping review - Lizzy Johnston
• Health Professionals’ Perceptions Regarding Chemotherapy and/or Radiation Therapy Related Mucositis (Mucosal Barrier Injury). - Michelle Kang
• Feasibility of implementing a pharmacist-led DPYD gene testing service for patients newly commencing 5-fluorouracil or capecitabine. - Benjamin Lee
• Modality preferences for healthy living after cancer interventions: a theoretical investigation - Morgan Leske
• Access to and Availability of Cancer Clinical Trials in Victoria, 2018 - Narelle McPhee
• Physical activity referral patterns and physical fitness levels of Clinical Oncology Society of Australia 2019 conference delegates - Andrew Murnane
• Lung cancer care pathway at Peninsula Health: A retrospective study - Sok Mian Ng
• Evaluation of initial virtual telephone clinics for new patient referrals at a large United Kingdom Phase 1 Cancer Clinical Trials Unit – A necessary innovation in the era of COVID-19 and social distancing - Abhijit Pal
• Evaluation of online patient education videos to assist decision making for patients considering trial participation at a United Kingdom Phase 1 Cancer Clinical Trials Unit – a useful tool in the era of COVID-19 and social distancing - Abhijit Pal
• Bench-marking the optimum utilization and demand for cancer surgery - Sathira Perera
• Self reported comorbidity in patients presenting to an Australian cancer centre - Graham Pitson
• Australian participation in multi-national phase 3 oncology trials as recorded by ClinicalTrials.gov - Graham Pitson
• Evaluation of patient access programs, uptake and usage across completed programs - Naji Salem
• Factors influencing patient decision-making for Risk-Reducing and Contralateral Prophylactic Mastectomies: Healthcare professionals’ perspectives - Ilona IJ Juraskova
• Outcomes in Lung Cancer - Rahul Solanki
• Patient utilisation of cancer therapies in Western New South Wales following introduction of remote video assisted chemotherapy (RVAC) - Samuel Stevens
• A study on the financial impact of dose banding implementation for systemic anti-cancer therapy in an Australian cancer specialty hospital - Whiter Tang
• An analysis of same-day cancellations of systemic anti-cancer therapy in a day therapy unit - Whiter Tang
• Real-time psychosocial impacts of COVID-19 on Australian cancer patients, survivors and carers - Carolyn Mazariego
• The psychosocial impact of COVID-19 on cancer communities and cancer care delivery (PEACH-C19) - April Morrow
• Understanding the practice and confidence level of community-based allied-health professionals in providing cancer care in Sydney: a cross sectional survey. - Kerry Tiller
• Assessing the COVID-19 impact on the management and treatment of cancer patients - Inga IT Tinton
• Digital technology as a tool in helping to provide healthcare services to patients in Australia - Inga IT Tinton
• The feasibility of exercise interventions delivered via Telehealth for people affected by cancer. - Kellie Toohey
• Science behind the policy: what is the scientific evidence for health-system interventions aiming to reduce delays in head and neck cancer diagnosis and treatment? - Rebecca L Venchiarutti
• Elective ICU admissions for organ donation in patients with terminal brain cancer: two cases illustrating barriers and facilitators - Shohei Waller
• Economic Assessment of a Symptom and Urgent Review Clinic - Georgina Akers
• Supporting Symptom and Urgent Review Clinics to respond to the impact of COVID-19 - Georgina Akers
• Patient and Carer Satisfaction of Outpatient VideoConference Services during COVID-19 Restrictions: A Rural Medical Oncology Perspective - Michele Delacretaz and Mihitha Ariyapperuma
• Clinical trial prescriptions: How long do they take to process? A time in motion study - Aimee Byrne
• The benefits of the clinical nurse consultant – Care coordinator. A 5 year KPI retrospective review. - Zoe Marie Johnson
• Use of social media and web-based support to provide continuity of care during a pandemic for Australian Neuroendocrine Cancer patients - Simone Leyden
• Improving the quality of care delivery during Peptide Receptor Radionuclide Therapy (PRRT) for patients with Neuroendocrine Neoplasms (NENs): development and implementation of personalised patient planners (PPS) to streamline complex multidisciplinary care. - Jessica Mercurio
• Development and implementation of a psychologist-led complex patient multi-disciplinary team meeting (CP-MDTM) to address unmet psychosocial needs of patients with cancer: experience from the Adem Crosby Cancer Centre, Sunshine Coast University Hospital and Health Service. - Rosanne Middleton
• Evaluation of an at-home patient infusion and support service, uptake and usage across Australia - Marc Mikhail
• The establishment of a physiotherapy telehealth service for education and lymphoedema monitoring of patients after breast cancer surgery - Leonie Naumann
• Victorian Aboriginal cancer cultural safety grants - Liz Simkiss
• Information needs of children with cancer and their parents for managing cancer-related symptoms: Preliminary findings of a systematic review. - Qamra Muaikel Alqahtani
• Title: Finding my way-advanced: usability testing of a self-guided web-based psychosocial program for women with metastatic breast cancer. - Lisa Beatty
• A review of the content and psychometric properties of patient-reported outcome measures (PROMs) used to assess cancer-related fatigue in intervention trials. - Rachel Campbell
• Interventions to support caregivers: A systematic review of family caregiver research during cancer. - Elisabeth Coyne
• Addition of netupitant to 5HT3-receptor antagonist/dexamethasone prophylaxis with FOLFOX reduces rates of chemotherapy-induced nausea and vomiting (CINV).  - Eunice Dai
• Effects of a prescribed, supervised exercise program on tumour disease progression in oncology patients undergoing anti-cancer therapy:  A retrospective observational cohort study - Daniella Dougherty
• ENABLE: ENhAncing lifestyle Behaviours in endometriaL cancEr: a pilot randomised controlled trial - Lara Edbrooke
• Implementation and evaluation of a nutrition care pathway for patients with retroperitoneal sarcoma. - Kate Graham
• Developing a revised Edmonton Symptom Assessment Scale for use with Culturally and Linguistically Diverse and Lower Literacy Patients with Cancer. - Sharon He
• An umbrella review of interventions for breast cancer survivors: Mapping available evidence according to the Quality of Cancer Survivorship Care Framework - Emma Kemp
• The impact of lifestyle interventions on health-related outcomes in older people with cancer: an umbrella review - Reegan Knowles
• Psychosocial experiences of lung cancer survivors: A qualitative study - Rebekah Laidsaar-Powell
• Nutritional status and considerations for patients diagnosed with a gastroenteropancreatic neuroendocrine tumour: Nutrition in NETs study - Erin Laing
• Financial toxicity as a side-effect of cancer – a Victorian profile of callers to a phone-based information and support line - Katherine Lane
• Psychosocial outcomes of cancer survivors with advanced colorectal cancer: A qualitative study - Chloe Y. S. Lim
• Helpful, but is it accessible? A qualitative study investigating the psychosocial support experienced by people living with advanced cancer - Jade C Newton
• Health related outcomes among participants in a digital health enabled multidisciplinary cancer support program - Danielle Parent
• Malnutrition, Physical Function, and Quality of Life During Chemotherapy for Metastatic Breast Cancer  - Jessica Parkinson
• Improving cancer-related head and neck lymphoedema management - the first steps   - Amanda Pigott
• Supportive care from breast care nurses: experiences and expectations of Australian women living with metastatic breast cancer - Andrea L Smith
• Perceptions of optimal care among Australian and Japanese cancer outpatients - Megumi Uchida
• Patterns and predictors of exercise following surgery for Breast Cancer - Jasmine Yee
• Effectiveness of a real-world exercise program for people post-hematopoietic stem cell transplantation - Jasmine Yee
• Interventions for cancer-related fatigue: a review of systematic reviews - Jasmine Yee
• NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. - Andrew Dean
• The interplay between inflammatory markers and body composition with six months of HIIT in breast, colorectal and prostate cancer survivors.  - Morgan J Farley
• Evaluation of the YMCA Cancer Survivors’ Program: a study protocol  - Eliza Keating
• ZENERGISE trial and COVID-19 tribulation: a snapshot of progress - Ashanya Malalasekera
• DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. - Shomik Sengupta
• CELEBRATE: A Phase 1b study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF-mutant metastatic melanoma (The CELEBRATE study) - Jennifer A Soon
• P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). - Shalini Subramaniam
• The Australian Rare Cancer Portal – a national framework for co-ordinating streamlined access to rare cancer clinical expertise and research - Rebecca Tay